Glycomics and Glycobiology Market Set for Strong Growth at 17.3% CAGR Through 2031, Led by North America's 41% Global Market Share | DataM Intelligence

The Global Glycomics and Glycobiology Market is expected to grow at a high CAGR of 17.3% during the forecast period 2024-2031.

Market growth is driven by increasing research in glycan-based biomarkers, rising applications in drug discovery and precision medicine, and growing investments in biotechnology and life sciences research. Additionally, advancements in analytical technologies, expanding use in oncology and immunology studies, and rising focus on understanding disease mechanisms at the molecular level are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glycomics-and-glycobiology-market?ram

United States: Key Industry Developments
✅ October 2025: Thermo Fisher Scientific launched an advanced glycomics analysis platform with AI-integrated mass spectrometry for faster glycan profiling in drug discovery, enhancing precision medicine applications in oncology.

✅ September 2025: Danaher Corporation expanded its glycobiology reagent portfolio with new high-throughput kits for glycan sequencing, supporting biopharmaceutical R&D amid rising demand for personalized therapeutics.

✅ August 2025: The National Institute of General Medical Sciences allocated $2.6 billion in funding to glycobiology research institutions, boosting collaborations for glycan-based therapeutics in infectious diseases.

Asia Pacific / Japan: Key Industry Developments
✅ October 2025: Shimadzu Corporation introduced next-generation glycomics instruments tailored for Japan's biopharma sector, focusing on automated glycan analyzers to accelerate vaccine development.

✅ September 2025: Chinese biotech firms secured major investments in glycomics for chronic disease diagnostics, with new facilities in Shanghai emphasizing multi-omics integration and production scale-up.

✅ August 2025: Japanese government subsidies supported glycobiology instrumentation R&D, enabling Unicharm-linked partners to innovate in glycan therapeutics aligned with national health policies.

Key Merges and Acquisitions(2025):
✅ Merck KGaA bolstered its glycobiology leadership by launching AI-enhanced GlycoProfile platforms and expanding glycan purification tools, enhancing biopharma quality control and high-throughput screening capabilities.

✅ GlycoNet forged a strategic partnership with CQDM in September 2024 to accelerate glycomics drug discovery and development in Canada, pooling resources for advanced technologies and improved healthcare outcomes.

✅ MilliporeSigma (Merck) introduced glycoengineering reagents and integrated AI-driven analytics for glycan mapping in early 2025, strengthening biotherapeutic development and biomarker research in the glycomics market.

Market Segmentation Analysis:
-By Product: Enzymes Lead with Dominant Share
Enzymes hold the largest market share at 35%, essential for glycan analysis due to their consumable nature and critical role in breaking down complex carbohydrates in research and diagnostics.
Instruments follow at 28%, including mass spectrometry (high sensitivity for structural analysis), chromatography (rapid separation advances), arrays, and others like electrophoresis and NMR, powering precise glycobiology workflows.
Kits claim 20%, with glycan releasing, labeling, purification, and others streamlining standardized protocols for labs; carbohydrates at 10% cover oligosaccharides, monosaccharides, and others like glycoproteins; reagents & chemicals at 7% support broad reactions.

-By Application: Drug Discovery Drives Growth
Drug Discovery & Development commands 55% share, fueled by glycan biomarkers for therapeutics and personalized medicine targeting cancer and immunology.
Disease Diagnostics holds 30%, leveraging glycomics for biomarker detection in oncology and infectious diseases.
Other Applications (virology, cell biology, microbiology) take 15%, expanding in research for viral glycans and cellular studies.

-By End-User: Pharma & Biotech Dominate
Pharmaceutical and Biotechnology Companies lead with 40% share, investing heavily in glycan-based drug pipelines and R&D.
Academic Research Institutes follow at 25%, driving foundational glycobiology studies and tech innovation.
Hospitals and Clinical Laboratories split the rest at 20% and 15%, focusing on diagnostics and patient testing.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=glycomics-and-glycobiology-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of chronic diseases like cancer and diabetes, which boosts demand for glycomics in diagnostics and therapeutics.

-Advancements in analytical technologies such as mass spectrometry and high-throughput screening, enabling precise glycan analysis.

-Increasing investments in R&D by pharmaceutical, biotechnology firms, and governments for drug discovery and novel therapeutics.

-Growing applications in personalized medicine, leveraging glycan biomarkers for tailored treatments and disease monitoring.

-Expansion of biopharmaceutical sector, particularly glyco-engineered biologics and vaccine development.

Regional Insights:
-North America holds the largest share of the Glycomics and Glycobiology Market, estimated at around 41% in recent years, driven by substantial R&D investments, a strong presence of key players in the US, and advanced biotechnology infrastructure.

-Europe follows as the second-largest region with approximately 28% market share, supported by robust research funding, collaborations in pharmaceutical and academic sectors, and growing applications in drug development across countries like Germany and the UK.

-Asia Pacific ranks third with about 23% share and the fastest growth rate, fueled by expanding healthcare infrastructure, rising investments in biotech hubs in China and India, and increasing demand for advanced diagnostics.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glycomics-and-glycobiology-market?ram

Key Players:
Merck KGaA | Agilent Technologies | Thermo Fisher Scientific | New England Biolabs | Shimadzu Corporation | Waters Corporation | Asparia Glycomics S.L. | Bruker Corporation | Chemily Glycoscience | Dextra Laboratories

Key Highlights (Top 5 Key Players) for Glycomics and Glycobiology Market:
-Merck KGaA reported annual revenues exceeding USD 24 billion, with the Life Science segment contributing over 45% linked to glycobiology tools like glycan analysis reagents and GlycoProfile kits.​

-Thermo Fisher Scientific leads with glycomics instruments and enzymes, supporting a market segment projected at USD 3.7 billion by 2027 amid biomarker and drug discovery growth.​

-Agilent Technologies drives glycomics through chromatography and mass spectrometry solutions, featured in reports valuing the overall market at USD 2.48 billion in 2022.​

-Waters Corporation contributes via advanced HPLC systems for glycan separation, operating in a sector expanding at 15.5% CAGR to USD 9.33 billion by 2032.​

-Bruker Corporation advances NMR and MS technologies for glycobiology research, aligning with North America's fast-growing regional dominance in glycomics applications.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.